NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known leptomeningeal disease (LMD); Patients with untreated, unstable, symptomatic CNS metastases that require treatment- see trial for details

Comments are closed.

Up ↑